FARN vs. SCLP, FUM, ETX, POLB, TRX, REDX, 4BB, AREC, C4XD, and AVCT
Should you be buying Faron Pharmaceuticals Oy stock or one of its competitors? The main competitors of Faron Pharmaceuticals Oy include Scancell (SCLP), Futura Medical (FUM), e-therapeutics (ETX), Poolbeg Pharma (POLB), Tissue Regenix Group (TRX), Redx Pharma (REDX), 4basebio (4BB), Arecor Therapeutics (AREC), C4X Discovery (C4XD), and Avacta Group (AVCT). These companies are all part of the "biotechnology" industry.
Scancell (LON:SCLP) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership.
Scancell has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500. Comparatively, Faron Pharmaceuticals Oy has a beta of -0.14, suggesting that its share price is 114% less volatile than the S&P 500.
45.7% of Scancell shares are held by institutional investors. Comparatively, 13.2% of Faron Pharmaceuticals Oy shares are held by institutional investors. 5.7% of Scancell shares are held by company insiders. Comparatively, 41.8% of Faron Pharmaceuticals Oy shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Scancell had 1 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 1 mentions for Scancell and 0 mentions for Faron Pharmaceuticals Oy. Scancell's average media sentiment score of 0.57 beat Faron Pharmaceuticals Oy's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.
Scancell's return on equity of 0.00% beat Faron Pharmaceuticals Oy's return on equity.
Scancell has higher revenue and earnings than Faron Pharmaceuticals Oy. Scancell is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.
Faron Pharmaceuticals Oy received 130 more outperform votes than Scancell when rated by MarketBeat users. Likewise, 77.51% of users gave Faron Pharmaceuticals Oy an outperform vote while only 74.50% of users gave Scancell an outperform vote.
Summary
Scancell beats Faron Pharmaceuticals Oy on 8 of the 14 factors compared between the two stocks.
Get Faron Pharmaceuticals Oy News Delivered to You Automatically
Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FARN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Faron Pharmaceuticals Oy Competitors List
Related Companies and Tools
